Z
Zentalis Pharmaceuticals, Inc. (ZNTL)
2.10
0.00 (0.00%)
Get all premium features to the best stock analysis tool
2.10
0.00 (0.00%)
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. Ingmar Bruns M.D., Ph.D. | Chief Medical Officer |
| Mr. Haibo Wang | Chief Business Officer |
| Mr. Henry Gu | Senior VP & Head of Intellectual Property |
| Mr. James B. Bucher J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Rajesh Israni | Executive VP of Regulatory Affairs & Medical Writing |
| Mr. Robert J. DiVasto P.E. | Chief Technical Officer |
| Mr. Vincent A. Vultaggio | SVP of Finance & Principal Accounting Officer |
| Date | Type | Document |
|---|---|---|
| 2026-01-09 | 8-K | zntl-20260106.htm |
| 2025-12-15 | 8-K | zntl-20251215.htm |
| 2025-11-10 | 10-Q | zntl-20250930.htm |
| 2025-08-26 | 8-K | zntl-20250826.htm |
| 2025-08-06 | 8-K | zntl-20250806.htm |
| 2025-06-18 | 8-K | zntl-20250617.htm |
| 2025-06-02 | 8-K | zntl-20250531.htm |
| 2025-05-23 | DEFA14A | zntldefa14a-2025proxyamend.htm |
| 2025-05-20 | 8-K | zntl-20250520.htm |
| 2025-05-14 | 10-Q | zntl-20250331.htm |
| Ms. Julie M. Eastland M.B.A. |
| CEO, President & Director |
| Ms. Wendy Chang | Chief People Officer |